Ibrutinib vs Venetoclax: A Better Approach for Relapse Disease?

The global message that I've been hearing for a while has been in terms of efficacy, at least in terms of BTK in general versus Venetoclax. Is there any data to suggest one is better than the other? No data. We have no head-to-head data prospectively. Any fixed-duration approach will probably have a modestly, if not statistically significant inferior progression-free survival to any continuous therapy BTK inhibitor approach we use.